Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASC36o
- Development stage
- Preclinical
- Lead developer
- Ascletis Pharma
- Modality
- Peptides
- Administration
- Oral
01
Overview
ASC36o is an orally bioavailable peptide agonist of the amylin receptor currently in the discovery stage for the treatment of obesity. Developed by Ascletis Pharma, the drug is designed to mimic the physiological actions of amylin, a peptide hormone co-secreted with insulin that regulates energy balance by promoting satiety and slowing gastric emptying. By utilizing an oral peptide formulation, ASC36o aims to provide a more convenient, non-invasive alternative to injectable amylin analogs or GLP-1 receptor agonists, potentially improving patient compliance and expanding the therapeutic options for weight management.
02
Targets
AMY receptor (Calcitonin receptor (with ramps))
Beyond the preview
Go deeper on ASC36o.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASC36o.